Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 6, 2010, Pages 39-44

  Cohen, Joel L ^a  

^a AboutSkin Dermatology and DermSurgery PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; AZATHIOPRINE; CYCLOSPORIN; ETRETIN; ETRETINATE; FLUOROURACIL; IMIQUIMOD; ISOTRETINOIN; PLACEBO; RETINOL;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CARBON DIOXIDE LASER; CARCINOGENICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CRYOTHERAPY; CURETTAGE; DRUG MEGADOSE; EARLY CANCER; EARLY INTERVENTION; GENETIC SIMILARITY; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSURVEILLANCE; MALIGNANT TRANSFORMATION; NEOPLASM; PHOTODYNAMIC THERAPY; REVIEW; RISK REDUCTION; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE;

EID: 77954494853     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):S4-S7.
2. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649-655.
3. Gupta AK, Cooper EA, Feldman SR, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis. 2002;70(2 Suppl):8-13.
4. Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32: 1045-1049.
5. The Lewin Group. The Burden of Skin Diseases: 2005. Falls Church, VA: The Lewin Group, for the Society for Investigative Dermatology and the American Academy of Dermatology Association; 2005.
6. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759-765.
7. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41:269-285.
8. Alam M, Ratner D. Cutaneous squamous cell carcinoma. N Engl J Med. 2001;344:975-983.
9. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46:895-904.
10. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer. 1997;79:920-923.
11. Czarnecki D, Meehan CJ, Bruce F, Culjak G. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg. 2002;6:207-209.
12. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37:677-681.
13. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797.
14. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127:1029-1031.
15. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007;33:1099-1101.
16. Criscione VD, Weinstock MA, Naylor MF, et al. Natural history and malignant progression of actinic keratoses: the VATTC trial [abstract 506]. J Invest Dermatol. 2008;128(Suppl 1):S85.
17. Sambandan PG, Goldman GD. Infiltrative basal cell carcinomas presenting as actinic keratosis: implications for clinical practice. Dermatol Surg. 2008;34:9-13.
18. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189-196.
19. Patients urged to seek treatment for actinic keratoses, recommends the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation. Cutis. 1999;63:348.
20. Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006;55(Suppl):1-8.
21. Jorizzo JL, Carney PS, Ko WT, et al. Treatment options in the management of actinic keratosis. Cutis. 2004;74(6 Suppl):9-17.
22. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6:949-956.
23. Lebwohl M, Tannis C, Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat. 2003;14(Suppl 2):3-6.
24. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633-1637.
25. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant. 2005;19:726-734.
26. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol. 2006;142:729-735.
27. Oseroff AR, Shieh S, Frawley NP, et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2005;141:60-67.
28. Apalla Z, Sotiriou E, Chovarda E, et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol. 2010;162:171-175.
29. Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142:976-982.
30. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev. 2000;9:1281-1286.
31. Arad S, Zattra E, Hebert J, et al. Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice. Am J Pathol. 2008;172:1248-1255.
32. Wolf P, Maier H, Mullegger RR, et al. Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-alpha. J Invest Dermatol. 2000;114:149-156.
33. Yarosh D, Bucana C, Cox P, et al. Localization of liposomes containing a DNA repair enzyme in murine skin. J Invest Dermatol. 1994;103:461-468.
34. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1-17.
35. Bouwes Bavinck JN, Euvrard S, Naldi L, et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol. 2007;127:1647-1656.
36. Oseroff A. PDT as a cytotoxic agent and biological response modifier: implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol. 2006;126:542-544.
37. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251-258.
38. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol. 2004;151:196-200.
39. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77:115-121.
40. de Graaf YG, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol. 2006;126:569-574.
41. Mehta S, Lee PK. ALA PDT for the chemoprevention of squamous cell carcinomas in chronically immunosuppressed solid organ transplant recipients at high risk of recurrence. Presented at: Combined Annual Meeting of the American Society of Dermatologic Surgery and American College of Mohs Micrographic Surgery and Cutaneous Oncology; October 27-30, 2005; Atlanta, GA.
42. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:1933-1938.
43. Gibson GE, O'Grady A, Kay EW, Murphy GM. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol. 1998;10:42-47.
44. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152:518-523.
45. Neuhaus IM, Tope WD. Practical retinoid chemoprophylaxis in solid organ transplant recipients. Dermatol Ther. 2005;18:28-33.
46. Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol. 1986;15(4 Pt 2):829-835.